Ignite Creation Date:
2024-05-05 @ 5:31 PM
Last Modification Date:
2024-10-26 @ 9:33 AM
Study NCT ID:
NCT00474786
Status:
COMPLETED
Last Update Posted:
2013-11-21
First Post:
2007-05-15
Brief Title:
Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib
Sponsor:
Pfizer
Organization:
Pfizer
Organization Data
Organization:
Pfizer
Class:
INDUSTRY
Study ID:
3066K1-404
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Pfizer
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None